Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03918356

Application of Electrical Impedance Myography (EIM) as a Potential Biomarker of Idiopathic Inflammatory Myopathies

Idiopathic Inflammatory Myopathies Clinical Trial

Official title:
Application of Electrical Impedance Myography (EIM) to Establish Muscle Impedance Parameters as a Potential Biomarker of Idiopathic Inflammatory Myopathies (IIMs)

Clinical Trial Summary

1. To assess changes in impedance parameters in Idiopathic Inflammatory Myopathies (IIMs). 2. To assess whether EIM parameters are reflective of disease severity, based on clinical outcome measures of IIMs.

Clinical Trial Description

1. To assess changes in impedance parameters in Idiopathic Inflammatory Myopathies (IIMs) There are structural and compositional changes in muscles, such as edema, adipose infiltration, and/or atrophy, in IIMs. Electrical impedance myography (EIM) is sensitive to such changes. EIM parameters will be different when compared to healthy controls in IIMs. 2. To assess whether EIM parameters are reflective of disease severity, based on clinical outcome measures of IIMs. Clinical outcome measures reflect on disease severity which is an indirect measure of muscle involvement in IIMs. If EIM parameters correlate with clinical outcome measure, it would indirectly prove that EIM can reflect disease severity in IIMs ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03918356
Study type Interventional
Source Yale University
Contact
Status Completed
Phase N/A
Start date June 1, 2019
Completion date May 30, 2021
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05833711 - Study Evaluating Efficacy and Safety of Froniglutide (PF1801) in Patients With Idiopathic Inflammatory Myopathy Phase 2
Recruiting NCT04561557 - Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System Early Phase 1
Completed NCT04208464 - JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult IIM Phase 2
Completed NCT03267277 - Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis Phase 2/Phase 3
Recruiting NCT06316076 - Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune Diseases Phase 1
Not yet recruiting NCT06350110 - Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE) Phase 1/Phase 2
Recruiting NCT05879419 - Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases Phase 4
Recruiting NCT04792931 - Adult Autoimmune Myopathies (MAIA) N/A
Not yet recruiting NCT06417398 - Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases Early Phase 1
Not yet recruiting NCT06285539 - Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases Phase 2
Recruiting NCT04664465 - PRediction Of DIverse Glucocorticoids toxIcity OUtcomeS
Not yet recruiting NCT06152172 - CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101 Phase 1
Recruiting NCT05400889 - Clinical Characteristics and Mechanism Research of Inhibitors of Janus Kinase in the Idiopathic Inflammatory Myopathies Phase 2
Completed NCT00341679 - Studies of the Natural History and Pathogenesis of Autoimmune/Connective Tissue Diseases
Recruiting NCT05952531 - Characterizing Myositis With 68Ga-FAPI PET/CT Early Phase 1
Recruiting NCT05200702 - Assessment of Safety and Acute Effects of a Knee-hip Powered Soft Exoskeleton in Patients With Neuromuscular Disorders N/A
Completed NCT03092167 - Physical Training in Patients With Idiopathic Inflammatory Myopathies N/A
Recruiting NCT03092180 - Optimizing Treatment on Idiopathic Inflammatory Myopathies
Recruiting NCT05199246 - Assessment of Safety and Acute Effects of a Lower-limb Powered Dermoskeleton in Patients With Neuromuscular Disorders N/A
Not yet recruiting NCT04034199 - Treating Idiopathic Inflammatory Myopathies Related Reduced Bone Mineral Density With Denosumab or Zoledronic Acid Phase 3